TITLE

AVI BioPharma/XTL Biopharmaceuticals to Develop Therapeutics

PUB. DATE
January 2000
SOURCE
Worldwide Biotech;Jan2000, Vol. 12 Issue 1, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the agreement signed by AVI BioPharma Inc. and XTL Biopharmaceuticals, Ltd. to combine strengths for the evaluation and co-development of therapeutics for hepatitis B and hepatitis C.
ACCESSION #
2685750

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;8/16/2011, Vol. 22 Issue 158, p3 

    The article presents updates on biomedical technology including a pivotal study by Allon Therapeutics Inc. of Vancouver B.C. of its neuroprotective drug candidate davunetide for progressive suprenuclear palsy, a Phase 2 study of eteplirsen by AVI BioPharma Inc. and the reported top-line results...

  • Results Update.  // PharmaWatch: Biotechnology;Nov2006, Vol. 5 Issue 11, p5 

    The article focuses on various developments related to the pharmaceutical industry. It has been reported by AVI BioPharma Inc. that the drug AVI-4065 has proved ineffective in the trial on patients with hepatitis C virus. In two of its investigational therapies for bone disease, promising data...

  • AVI drops hepatitis C trial to focus on Neugene.  // PharmaWatch: Biotechnology;Sep2007, Vol. 6 Issue 9, p22 

    The article offers corporate updates for AVI BioPharma Inc. in the U. S. The company drops its planned dose-escalating hepatitis C trial to focus on development of its Neugene candidates for cardiovascular and genetic diseases, as part of its strategic refocusing. Interim chief executive officer...

  • Global Therapeutics uses best of DES, BMS for stent.  // Medical Technology & Devices Week;8/20/2007, Vol. 5 Issue 34, p2 

    The article reports on the integration of the drug-eluting stent and bare metal stent technologies by Global Therapeutics. With the integration, the company was able to create a new stent system that employs a follow-on an antisense agent, developed by AVI BioPharma, to arrest the process of...

  • Research & Markets: Muscular Dystrophy -- Pipeline Review, H2 2011.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article offers information on a report "Muscular Dystrophy -- Pipeline Review, H2 2011" published by the company Global Markets Direct. This report provides information related to the therapeutic development for muscular dystrophy with latest updates and special features. It reviews the...

  • Other News To Note.  // BioWorld Today;11/7/2011, Vol. 22 Issue 216, p5 

    This section offers news briefs from the biotechnology business sector including the findings by MiRagen Therapeutics Inc. on microRNA in relation to heart attack and the agreement signed by XTL Biopharmaceuticals to buy NiCure technology from Mor Research Applications.

  • AVI BIOPHARMA MODIFIES HEPATITIS C VIRUS CLINICAL STUDY.  // Biotech Business;Sep2006, Vol. 19 Issue 9, p1 

    No abstract available.

  • CLINIC ROUNDUP.  // BioWorld Today;12/27/2007, Vol. 18 Issue 249, p3 

    This section provides updates on clinical trials in the biotechnology industry as of December 27, 2007. AVI BioPharma Inc. dosed the first patient in a proof-of-concept trial of AVI-4658 in Duchennes muscular dystrophy. Sinovac Biotech Ltd. reported positive top-line results from its Phase II...

  • Clinic Roundup.  // BioWorld Today;6/10/2011, Vol. 22 Issue 112, p4 

    This section offers biotechnology industry news briefs as of June 10, 2011. The institutional review board (IRB) for AVI Biopharma Inc.'s planned Phase II trial of exon-skipping therapy eteplirsen in Duchenne's muscular dystrophy requested that AVI should alter the trial protocol. ImmunoCellular...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics